Onconetix Future Growth
Future criteria checks 0/6
Onconetix's earnings are forecast to decline at 17% per annum while its annual revenue is expected to grow at 84.4% per year. EPS is expected to decline by 7.8% per annum.
Key information
-17.0%
Earnings growth rate
-7.8%
EPS growth rate
Biotechs earnings growth | 30.1% |
Revenue growth rate | 84.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 08 Nov 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -26 | N/A | N/A | 1 |
12/31/2025 | N/A | -20 | N/A | N/A | 1 |
12/31/2024 | N/A | -16 | N/A | N/A | 1 |
12/31/2023 | N/A | -13 | N/A | N/A | 1 |
9/30/2023 | N/A | -18 | -22 | -12 | N/A |
6/30/2023 | N/A | -17 | -20 | -11 | N/A |
3/31/2023 | N/A | -14 | -12 | -12 | N/A |
12/31/2022 | N/A | -14 | -9 | -9 | N/A |
9/30/2022 | N/A | -12 | -7 | -7 | N/A |
6/30/2022 | N/A | -9 | -5 | -5 | N/A |
3/31/2022 | N/A | -6 | -3 | -3 | N/A |
12/31/2021 | N/A | -4 | -2 | -2 | N/A |
9/30/2021 | N/A | -3 | -2 | -2 | N/A |
6/30/2021 | N/A | -2 | -1 | -1 | N/A |
3/31/2021 | N/A | -2 | -1 | -1 | N/A |
12/31/2020 | N/A | -2 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: J4T is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: J4T is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: J4T is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: J4T is forecast to have no revenue next year.
High Growth Revenue: J4T is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if J4T's Return on Equity is forecast to be high in 3 years time